Acesso livre
Acesso livre

Arquivos do dia: Novembro 24, 2021

OMS emite diretrizes sobre o tratamento de crianças com síndrome inflamatória multissistêmica associada a COVID-19.

24 Nov, 2021 | 11:37h

Comunicado de imprensa: WHO issues guidelines on the treatment of children with multisystem inflammatory syndrome associated with COVID-19 – World Health Organization

Diretriz: Living guidance for clinical management of COVID-19 – World Health Organziation

Conteúdos relacionados:

An Update on Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2.

Ten Things to Know About Multisystem Inflammatory Syndrome in Children (MIS-C).

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.

Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.

Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.

Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

Neurologic involvement in children and adolescents with COVID-19 or Multisystem Inflammatory Syndrome

Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children

Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19

Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)

SR: Multisystem inflammatory syndrome in children related to COVID-19

Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children

ACR Guidance for pediatric patients with multisystem inflammatory syndrome in children associated with SARS‐CoV‐2

New systematic review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 infection summarizes the clinical features, management, and outcomes of the disease, showing favorable outcomes for the majority of children

Opinião de 32 ministros de saúde: o mundo precisa agir agora e se preparar para futuras emergências de saúde.

24 Nov, 2021 | 11:36h

The world must act now to be prepared for future health emergencies – The BMJ

Conteúdos relacionados:

Viewpoint | Strengthening global health security and reforming the international health regulations: making the world safer from future pandemics.

Perspective | Learning from crisis: building resilient systems to combat future pandemics.

Systematic review: Border controls, restricted entry, quarantine essential for curbing COVID-19 and future pandemics.

Opinion | The future of pandemic preparedness: agile coordination around clinical trials.

UN Report: Preventing the Next Pandemic – Zoonotic Diseases and How to Break the Chain of Transmission

 

Comentário no Twitter

 

Revisão | Infecção fúngica invasiva associada à COVID-19.

24 Nov, 2021 | 11:34h

COVID-19-associated Invasive Fungal Infection – Open Forum Infectious Diseases

Conteúdos relacionados:

Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis.

M-A: Incidence and mortality of COVID‐19‐associated pulmonary aspergillosis – The incidence and mortality in the ICU were estimated to be 10.2% and 54.9%, respectively.

Consensus Guideline: Defining and managing COVID-19-associated pulmonary aspergillosis

Bacterial and fungal superinfections in critically ill patients with COVID-19

Invasive Fungal Disease complicating COVID-19: when it rains it pours

A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU

Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients

 

Comentário no Twitter

 

Promoção da aceitação das vacinas contra COVID-19: recomendações da comissão do Lancet sobre recusa de vacina, aceitação e demanda nos EUA.

24 Nov, 2021 | 11:32h

Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA – The Lancet

Conteúdo relacionado: WHO Guidance for improving acceptance and uptake of COVID-19 vaccines

Esperava-se que pessoas com asma sofressem mais durante a pandemia de COVID. No entanto, isso não ocorreu.

24 Nov, 2021 | 11:31h

We expected people with asthma to fare worse during COVID. Turns out they’ve had a break – The Conversation

Atualização em prática clínica da AGA sobre tratamento da dor gastrintestinal crônica nos distúrbios de interação intestino–cérebro.

24 Nov, 2021 | 11:30h

AGA Clinical Practice Update on Management of Chronic Gastrointestinal Pain in Disorders of Gut–Brain Interaction: Expert Review – Clinical Gastroenterology and Hepatology

Estudo de coorte mostra que o risco de infarto miocárdico pode ser mais bem previsto pela apolipoproteína B.

24 Nov, 2021 | 11:28h

Association of Apolipoprotein B–Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content – JAMA Cardiology (link para o resumo – $ para o texto completo)

Comentários:

ApoB Gains Ground as Best Lipid Predictor of MI Risk – TCTMD

Study finds risk of MI best captured by number of apolipoprotein B lipoproteins – MedicalResearch

 

Comentário no Twitter

 

Ponto de vista | O crescente fenômeno da atenção primária “virtual primeiro”.

24 Nov, 2021 | 11:27h

The Growing Phenomenon of “Virtual-First” Primary Care – JAMA (gratuito por tempo limitado)

Três sociedades neurológicas, incluindo a AAN, emitem forte diretriz de posicionamento sobre o aducanumabe.

24 Nov, 2021 | 11:25h

Three Neurologic Societies, Including the AAN, Issue Strong Position Statement on Aducanumab – Neurology Today

Ver diretriz: Decisions With Patients and Families Regarding Aducanumab in Alzheimer Disease, With Recommendations for Consent: AAN Position Statement – Neurology

Conteúdos relacionados:

Editorial: Aducanumab for Alzheimer’s disease?

FDA approvement of Alzheimer’s drug sparks controversy among doctors.

 

Comentário no Twitter

 

Análise de segurança de estudos randomizados mostrou que o aducanumabe (medicamento para Alzheimer) causou edema cerebral em 35% dos pacientes e sintomas associados (cefaleia, confusão, tontura e náusea) em 26%.

24 Nov, 2021 | 11:24h

Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease – JAMA Neurology

Comentário: Biogen Alzheimer’s drug shows brain swelling in 35% of patients – MedicalXpress

 

Comentário no Twitter

 

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.